12/29/2023 0 Comments Fasttrack schedule version 4![]() Press Release: Annual General Meeting of May 3, 2022.Media Update: Rezurock® (belumosudil) patient-reported outcomes correlated with clinical response in chronic graft-versus-host disease.Sanofi’s Board of Directors proposes the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent Directors.FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease. ![]() Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis.CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation.Nexviazyme® (avalglucosidase alfa) shows sustained improvements in respiratory function and mobility in patients with Pompe disease.Press Release: Strong 2021 sales and business EPS growth enabling increased investment in R&D.Press Release: Dupixent® (dupilumab) approved by European Commission for children aged 6 to 11 years with severe asthma with type 2 inflammation.Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine.Positive Dupixent® (dupilumab) data across five diseases with underlying type 2 inflammation to be presented at 2022 AAAAI Annual Meeting.New preclinical tolebrutinib data demonstrated superior brain penetration and potency.Availability of the Q4 2021 Memorandum for modelling purposes.Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria.Press Release: Sanofi successfully priced an inaugural sustainability-linked bond indexed on access to medicines.Press Release: Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board.Sanofi and Regeneron provide regulatory update on Libtayo® (cemiplimab-rwlc) in advanced cervical cancer.Press Release: Positive Phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine.Nirsevimab EMA regulatory submission accepted under accelerated assessment for RSV protection in all infants.Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines.Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Press Release: Sanofi continues to deliver strong business EPS growth driven by higher sales and improved margins in Q1.Press Release: EUROAPI listing on Euronext Paris expected on May 6, 2022.Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program.Olipudase alfa shown to provide sustained improvement across multiple clinical manifestations of ASMD.Press Release: FDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |